{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:59:52Z","timestamp":1793177992300,"version":"4.5.0"},"reference-count":15,"publisher":"BMJ","issue":"7","funder":[{"name":"Research Fund of Guangdong Pharmaceutical Association","award":["2021ZX01"],"award-info":[{"award-number":["2021ZX01"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:p>We examined case reports of immune checkpoint inhibitors (ICIs) associated pulmonary tuberculosis (PT) using data from the Food and Drug Administration Adverse Event Reporting System database. Disproportionality analysis was performed by using the reporting OR (ROR) with relevant 95% CI. A total of 74 cases of PT related to ICIs therapy were identified. ICIs were significantly associated with over-reporting frequencies of PT (ROR=3.16, 95%\u2009CI: 2.51 to 3.98), while the signal was differed between anti-programmed death-1\/ligand-1 and anti-cytotoxic T lymphocyte antigen-4 agents. Most indications were lung cancer (64.9%), the median onset age was 70 years, the median time to onset of PT was 70 days, ICIs were discontinued in most cases (85.2%).<\/jats:p>","DOI":"10.1136\/thoraxjnl-2021-217575","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T13:25:29Z","timestamp":1647005129000},"page":"721-723","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Pulmonary tuberculosis associated with immune checkpoint inhibitors: a pharmacovigilance study"],"prefix":"10.1136","volume":"77","author":[{"given":"Jianhong","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaifeng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"key":"2023100202100897000_77.7.721.1","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S1470-2045(20)30107-8","article-title":"Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research","volume":"21","author":"Johnson","year":"2020","journal-title":"Lancet Oncol"},{"key":"2023100202100897000_77.7.721.2","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00262-020-02726-1","article-title":"Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review","volume":"70","author":"Suliman","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"2023100202100897000_77.7.721.3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2217\/imt-2020-0061","article-title":"Reactivation of TB during administration of durvalumab after chemoradiotherapy for non-small-cell lung cancer: a case report","volume":"12","author":"Kato","year":"2020","journal-title":"Immunotherapy"},{"key":"2023100202100897000_77.7.721.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.07.006"},{"key":"2023100202100897000_77.7.721.5","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00659","article-title":"Tuberculosis infection in a patient treated with nivolumab for non-small cell lung cancer: case report and literature review","volume":"9","author":"van Eeden","year":"2019","journal-title":"Front Oncol"},{"key":"2023100202100897000_77.7.721.6","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","article-title":"EGFR-TKI-Associated interstitial pneumonitis in Nivolumab-Treated patients with non-small cell lung cancer","volume":"4","author":"Oshima","year":"2018","journal-title":"JAMA Oncol"},{"key":"2023100202100897000_77.7.721.7","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100951","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: a safety analysis of clinical trials and FDA pharmacovigilance database","volume":"37","author":"Zhu","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2023100202100897000_77.7.721.8","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0754-2"},{"key":"2023100202100897000_77.7.721.9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA - Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications","volume":"11","author":"B\u00f6hm","year":"2016","journal-title":"PLoS One"},{"key":"2023100202100897000_77.7.721.10","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1007\/s00262-020-02687-5","article-title":"Increased Th17 activation and gut microbiota diversity are associated with pembrolizumab-triggered tuberculosis","volume":"69","author":"Zhang","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"2023100202100897000_77.7.721.11","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2017.60"},{"key":"2023100202100897000_77.7.721.12","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1250LE"},{"key":"2023100202100897000_77.7.721.13","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abf3861"},{"key":"2023100202100897000_77.7.721.14","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.52668","article-title":"Anti-Pd-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-\u03b1","volume":"9","author":"Tezera","year":"2020","journal-title":"Elife"},{"key":"2023100202100897000_77.7.721.15","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30360-4"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thoraxjnl-2021-217575","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:11:33Z","timestamp":1696223493000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thoraxjnl-2021-217575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,11]]},"references-count":15,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,6,15]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1136\/thoraxjnl-2021-217575"],"URL":"https:\/\/doi.org\/10.1136\/thoraxjnl-2021-217575","relation":{"is-referenced-by":[{"id-type":"doi","id":"10.7554\/eLife.108175.2","asserted-by":"object"}]},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,11]]}}}